Journey Medical Co. (NASDAQ: DERM) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $9.00 price target on the stock.
Journey Medical Corporation (DERM)
Last journey medical corporation earnings: 11/5 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.dermira.com
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
DERM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DERM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DERM alerts
High impacting Journey Medical Corporation news events
Weekly update
A roundup of the hottest topics
DERM
News
- Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of RosaceaGlobeNewswire
- Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025GlobeNewswire
- Journey Medical Corporation to Participate in the 37th Annual ROTH ConferenceGlobeNewswire
- Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat RosaceaGlobeNewswire
- Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida [Yahoo! Finance]Yahoo! Finance
DERM
Earnings
- 11/12/24 - Beat
DERM
Sec Filings
- 3/24/25 - Form 8-K
- 3/11/25 - Form 4
- 3/10/25 - Form 4
- DERM's page on the SEC website